drugset / Trial / NCT01104779

Safety and Efficacy of Cariprazine in Schizophrenia

NCT01104779

Phase 3 Completed 446 enrolled Forest Laboratories Gedeon Richter Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.

Timeline

Start
2010-04-27
Primary completion
2011-12-15
Completion
2011-12-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 3 mg Oral
Subject Cariprazine Small molecule 6 mg Oral
Subject Cariprazine Small molecule 9 mg Oral

Indications